12 Dec 2022
22:01 CET |
ARGENX SE |
argenx Appoints Ana Cespedes to Board of Directors
|
20103010 Biotechnology |
Other subject |
10 Dec 2022
17:30 CET |
ARGENX SE |
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
|
20103010 Biotechnology |
Other subject |
30 Nov 2022
07:00 CET |
ARGENX SE |
argenx Enters Into Agreement To Acquire Priority Review Voucher
|
20103010 Biotechnology |
Other subject |
22 Nov 2022
07:00 CET |
ARGENX SE |
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
|
20103010 Biotechnology |
Other subject |
07 Nov 2022
07:00 CET |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
27 Oct 2022
07:00 CEST |
ARGENX SE |
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
|
20103010 Biotechnology |
Other subject |
20 Oct 2022
07:00 CEST |
ARGENX SE |
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
|
20103010 Biotechnology |
Other subject |
21 Sep 2022
07:00 CEST |
ARGENX SE |
argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
21 Sep 2022
07:00 CEST |
ARGENX SE |
argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings
|
20103010 Biotechnology |
Other subject |
08 Sep 2022
20:10 CEST |
ARGENX SE |
argenx Appoints Camilla Sylvest to Board of Directors
|
20103010 Biotechnology |
Other subject |
31 Aug 2022
07:00 CEST |
ARGENX SE |
argenx to Present at Wells Fargo Healthcare Conference
|
20103010 Biotechnology |
Other subject |
11 Aug 2022
13:00 CEST |
ARGENX SE |
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
28 Jul 2022
08:30 CEST |
ARGENX SE |
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
|
20103010 Biotechnology |
Other subject |
28 Jul 2022
07:00 CEST |
ARGENX SE |
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
|
20103010 Biotechnology |
Other subject |
21 Jul 2022
07:00 CEST |
ARGENX SE |
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
|
20103010 Biotechnology |
Other subject |
24 Jun 2022
07:00 CEST |
ARGENX SE |
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
|
20103010 Biotechnology |
Other subject |
01 Jun 2022
07:00 CEST |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
31 May 2022
07:00 CEST |
ARGENX SE |
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
19 May 2022
13:00 CEST |
ARGENX SE |
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
|
20103010 Biotechnology |
Other subject |
10 May 2022
23:30 CEST |
ARGENX SE |
argenx announces results of Annual General Meeting of Shareholders
|
20103010 Biotechnology |
Other subject |
05 May 2022
07:00 CEST |
ARGENX SE |
argenx Reports First Quarter 2022 Financial Results and Provides Business Update
|
20103010 Biotechnology |
Other subject |
05 May 2022
07:00 CEST |
ARGENX SE |
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia
|
20103010 Biotechnology |
Other subject |
04 May 2022
07:00 CEST |
ARGENX SE |
argenx to Present at BofA Securities 2022 Healthcare Conference
|
20103010 Biotechnology |
Other subject |
28 Apr 2022
07:00 CEST |
ARGENX SE |
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022
|
20103010 Biotechnology |
Other subject |
05 Apr 2022
07:00 CEST |
ARGENX SE |
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting
|
20103010 Biotechnology |
Other subject |
01 Apr 2022
07:00 CEST |
ARGENX SE |
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
|
20103010 Biotechnology |
Meetings / events |
29 Mar 2022
23:00 CEST |
ARGENX SE |
argenx announces full exercise of underwriters’ option to purchase additional ADSs
|
20103010 Biotechnology |
Other subject |
29 Mar 2022
22:30 CEST |
ARGENX SE |
argenx announces Annual General Meeting of Shareholders on May 10, 2022
|
20103010 Biotechnology |
Other subject |
28 Mar 2022
22:30 CEST |
ARGENX SE |
argenx announces closing of global offering
|
20103010 Biotechnology |
Other subject |
24 Mar 2022
02:00 CET |
ARGENX SE |
argenx raises $700 million in gross proceeds in a global offering
|
20103010 Biotechnology |
Other subject |
22 Mar 2022
21:15 CET |
ARGENX SE |
argenx announces launch of proposed global offering
|
20103010 Biotechnology |
Other subject |
22 Mar 2022
07:00 CET |
ARGENX SE |
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
03 Mar 2022
07:00 CET |
ARGENX SE |
argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update
|
20103010 Biotechnology |
Other subject |
28 Feb 2022
07:00 CET |
ARGENX SE |
argenx to Present at the 42nd Annual Cowen Health Care Conference
|
20103010 Biotechnology |
Other subject |
24 Feb 2022
07:00 CET |
ARGENX SE |
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
|
20103010 Biotechnology |
Other subject |
10 Feb 2022
07:00 CET |
ARGENX SE |
argenx to Present at the 11th Annual SVB Leerink Global Healthcare Conference
|
20103010 Biotechnology |
Other subject |
20 Jan 2022
08:00 CET |
ARGENX SE |
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
|
20103010 Biotechnology |
New |
07 Jan 2022
07:00 CET |
ARGENX SE |
argenx Highlights Strategic Priorities for 2022
|
20103010 Biotechnology |
New establishment |
03 Jan 2022
07:00 CET |
ARGENX SE |
argenx to Present at 40th Annual J.P. Morgan Healthcare Conference
|
20103010 Biotechnology |
Other subject |
17 Dec 2021
23:09 CET |
ARGENX SE |
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Meetings / events |
10 Nov 2021
07:00 CET |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
28 Oct 2021
07:00 CEST |
ARGENX SE |
argenx Reports Third Quarter 2021 Financial Results and Provides Business Update
|
20103010 Biotechnology |
Other subject |
21 Oct 2021
07:00 CEST |
ARGENX SE |
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
|
20103010 Biotechnology |
Other subject |
08 Oct 2021
07:00 CEST |
ARGENX SE |
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
|
20103010 Biotechnology |
Other subject |
03 Sep 2021
07:00 CEST |
ARGENX SE |
argenx to Present at Upcoming Investor Conferences
|
20103010 Biotechnology |
Other subject |
25 Aug 2021
07:00 CEST |
ARGENX SE |
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
|
20103010 Biotechnology |
Other subject |
04 Aug 2021
07:00 CEST |
ARGENX SE |
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
|
20103010 Biotechnology |
Other subject |
29 Jul 2021
07:00 CEST |
ARGENX SE |
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
|
20103010 Biotechnology |
Other subject |
22 Jul 2021
07:00 CEST |
ARGENX SE |
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
|
20103010 Biotechnology |
Other subject |
14 Jul 2021
07:00 CEST |
ARGENX SE |
argenx to Host Virtual R&D Day on July 20, 2021
|
20103010 Biotechnology |
Other subject |